Outlook Therapeutics, Inc. (OTLK) is a biopharmaceutical company primarily focused on the development and commercialization of innovative monoclonal antibody therapies for the treatment of ocular diseases. The company, formerly known as Oncobiologics, Inc., underwent a name change in 2018 to better reflect its enhanced focus on developing life-changing ophthalmic therapies.
The flagship product of Outlook Therapeutics is ONS-5010 / LYTENAVA™ (an “in-house” name pending FDA Acceptance), a proprietary ophthalmic formulation of bevacizumab. Outlook Therapeutics aims for LYTENAVA™ to be the first FDA-approved ophthalmic formulation of bevacizumab-vikg to treat wet age-related macular degeneration (wet AMD) and other retinal diseases. Wet AMD, a significant cause of vision loss in people aged 60 years and older, currently has limited treatment options, highlighting the groundbreaking potential for LYTENAVA™.
The company was founded in 2010 and later went public in 2016. Currently headquartered in Iselin, New Jersey, Outlook Therapeutics has assembled a team of seasoned experts to make its vision a reality, led by Lawrence A. Kenyon as President, CEO, CFO and Treasurer. The team combines years of experience in ophthalmic drug development with business acumen to unlock the value of its unique research platform in targeted medical therapies.
Outlook Therapeutics operates in a rapidly evolving sector, faced with challenging competition. Yet, the company's innovative and patient-centric position gives it a unique advantage. It is at the cutting edge of its sector, leading the way in addressing an unmet medical need by bringing to market a quality-assured, less expensive, responsibly labelled, FDA-approved ophthalmic formulation of bevacizumab.
The company’s tasks ahead are significant. They are working fervently to finish clinical trials and to secure FDA approval for ONS-5010 / LYTENAVA™. Despite the challenges faced, Outlook Therapeutics holds steadfast in their mission to develop viable treatments for ocular diseases and extend hope to those suffering from conditions like wet AMD. Their ultimate goal is to provide new clinical solutions that can help improve patients’ vision and quality of life.